Awesome Stock Sponsert EAPH
Seite 1 von 2 Neuester Beitrag: 24.04.21 23:12 | ||||
| Eröffnet am: | 05.06.13 11:24 | von: Forscher | Anzahl Beiträge: | 30 |
| Neuester Beitrag: | 24.04.21 23:12 | von: Franziskaxm. | Leser gesamt: | 14.451 |
| Forum: | Hot-Stocks | Leser heute: | 5 | |
| Bewertet mit: |  | |||
| Seite: < | 2 > | ||||
EAPH is our New Awesome Pick this week and it looks to be the Hottest Undervalued Sub Penny Pharma-Play in the Micro-Cap markets.
EAPH flagship product, VIORRA, is an over-the-counter aid to help restore and improve vaginal moisture and elasticity which plays an important role in women’s sexual desire and arousal, FSAD (Female-Sexual-Arousal-Disorder). The world market for products which treat this disorder is in excess of US$2 BB.
Members whats so great about EAPH is that its market cap is dirt cheap and still UNDER $1MM. Yes you read that right, we have found the Next Mega hidden Wallstreet gem, EAPH, with Mega upside potential having a product that could be considered the Next V-I-A-G-R-A for Women.
EAPH proprietary gel formulation is an innovative and unique transdermal delivery system. EAPH flagship product, VIORRA is a topical, daily-use product classified by the US Food and Drug Administration (FDA) as containing Generally Recognized as Safe ingredients.
EAPH is an undiscovered wallstreet gem that's on the verge of a mega breakout with both exciting breaking news and upside potential. EAPH could be the Next most talked about Micro-Cap play having a super small float (only 63 MM) and Outstanding share count (only 128MM) as of May 2013 via http://www.otcmarkets.com/stock/EAPH/company-info.
EAPH - Record Breaking News just Released Tonight
Easton Pharmaceuticals Announces Neil Mellor as Senior Consultant, Chief Operations Officer
TORONTO--(BUSINESS WIRE)--Easton Pharmaceuticals (EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, announced today that Mr. Neil Mellor will join the company as Senior Consultant, Chief Operations Officer. Mr. Mellor has over 25 years of experience in the pharmaceutical industry, both in Canada and Europe. The majority of Mr. Mellor’s background is in sales, marketing and business development for companies such as Merck, Pharmacia (now Pfizer), and Solvay Pharma (now Abbott Laboratories).
Over the past 10 years, Mr. Mellor has been Associate Director of Business Development at Solvay Pharma. In addition, Mr. Mellor served as President of the Canadian Healthcare Licensing Association (CHLA) from 2007 to 2008 and remains an active member of the Board of the CHLA. Mr. Mellor is currently the President of Global Health Link, a healthcare consulting company serving Canadian and US clients. We are especially pleased to have such an accomplished professional as Mr. Mellor on board to help with our future plans for our products, beginning with our lead product VIORRA TM,” commented Mr. John Adams, of Easton Pharmaceuticals’. "Mr. Mellor’s vast experience in marketing and licensing will help us navigate the sometimes uncertain waters of the different markets Easton Pharmaceuticals is considering, and will help us focus on the design and execution of key business activities which will enrich our pending commercialization efforts.”
About Easton Pharmaceuticals Inc (EAPH):
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding numbers of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins. The world market for these conditions is in excess of US$10 BB.
The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals’ flagship product, VIORRA, is an over-the-counter aid to help restore and improve vaginal moisture and elasticity which plays an important role in women’s sexual desire and arousal , FSAD (Female-Sexual-Arousal-Disorder). The world market for products which treat this disorder is in excess of US$2 BB. VIORRA is a topical, daily-use product classified by the US Food and Drug Administration (FDA) as containing Generally Recognized as Safe ingredients.
For more information, visit http://www.eastonpharma.com or http://www.ashleybiomedical.com
Contact:
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email and Media Relations: info@lamindustries.com
Email and Media Relations: info@ashleybiomedical.com
Contact:
Easton Pharmaceuticals Inc.
Dragoslav Milanovic, CEO
+1-416-619-0291
+1-347-284-0192
orMedia Relations:
info@lamindustries.com
or
info@ashleybiomedical.com
Optionen
| Boardmail an "Joerg100877" |
Wertpapier: Easton Pharmaceuticals |
EAPH hatte heute super news! einzusehen hier:
http://ih.advfn.com/p.php?pid=nmona&article=58929793
Ich persönlich sehe EAPH in den nächsten Tagen definitiv wieder über einem Cent. Wir werden sehen!
With just a quick glance at a chart of Easton Pharmaceuticals Inc. (OTCMKTS:EAPH), it may appear as if the stock was still spinning wheels, drifting listlessly between $0.005 and $0.012. The longer you look at a chart of EAPH, however, the more you have to wonder if a bullish paradigm shift is underway.
For those not familiar with the company, EAPH is a biopharma name. Its claim to fame is small but well-received library of topical treatments for everything from sexual dysfunction to stretch marks to varicose veins... creams and ointments created when the company was operating under the moniker LAM Industries. Its name was changed in 2010 to Easton Pharmaceuticals, though technically speaking, it doesn't have any actual FDA-approved, internally-administered drugs in its portfolio.... or didn't, anyway. The company is wading back into drug waters, taking the medical marijuana route.
Biotech trading veterans will know how big of a deal that could be for Easton Pharmaceuticals and EAPH shareholders. The advent of legalized marijuana - mostly for medicinal purposes, but also for recreational uses in some states - has put hemp and marijuana stocks at center stage for nearly a year now, and has been very good for those related stocks. EAPH didn't participate in most of that euphoria, as it only announced it was developing a medical marijuana product until early June, and didn't offer any real details of its plans until late August.
The timing and news are academic at this point, however. What matters most now, to us, are the bullish hints the chart is dropping... they're pointing to more upside.
Since early August when Easton Pharmaceuticals put itself back on the map by announcing it was getting into the medical marijuana race, we've seen a string of higher lows; we're also working higher highs (we've already made one higher high). At the same time, the volume the stock's been producing since the news made the company 'real' is noticeable better than the volume we were seeing before the news. Finally, Easton Pharmaceuticals is now finding support at its key long-term moving average lines like the 100-day line (gray) and the 200-day moving average line (green).
It admittedly doesn't seem like much to go on, but often, the subtle clues are the best ones. EAPH is slowly but surely on the mend. In fact, it's already mended - now it's just firming up its foundation from which it can stage an even bigger rally. It may not seem like much right now, but Easton Pharmaceuticals is setting itself up to be one of Q4's better Cinderella stories.
Da kann man sich jetzt noch zum Schnäppchenpreis einkaufen.
Wer weiß, wie lange noch...?!
NEIL MELLOR,WON'T RISK HIS PERFECT REPUTATION.called EAPH a scam or a pump this is Completely incorrect.Neil Mellor is a pharmaceutical executive with over 25 years experience in sales, marketing and business development, both in Canada and Europe. Neil's leadership has driven the successful performance of some of the world's biggest prescription drug brands for companies like GSK-GlazoSmithKline, Pfizer, and Abbott Laboratories.
Neil has extensive experience managing products in the CNS, cardiovascular and GI areas. Some of Neil's greatest success in the market came during his management of Pantoloc (Protonix), which attained sales of +$300m and became the #2 pharmaceutical product in Canada.
EAPH a life changer possibility 3 pending PR on EAPH >>JV ,50 % acquisition of new product ,viorra launch-Women Viagra ..NEIL the new CFO has big plans.very primed resume.
EAPH's fin.(Assets/liabilities ratio),ever better than others MJ companies: one of then trading .15 (145M CAP,950M A/S).other one trading 50 cents(20m cap,100m A/S).the first one have rev. the other one hasn't.
SO WHY THOSE COMPANIES TRADING SO HIGH(Although some of then has no rev.)? THE ANSWER IS THAT THE MARKET LOOKING FOR BIG FUTURE REV.
The energy industry newsletter ‘Energy And Capital’ declared stock market investments in marijuana companies to be on the rise"
the medical Marijuana industry could reach nearly $9 billion nationwide in five years, as more states in the United States clear the way to likely legalize marijuana for medicinal purposes
EAPH still a newborn at that area but lots of developmets hits since then:
Aug 23, 2013 Easton Pharmaceuticals, Inc. Provides Update on Its Medical Marijuana Initiatives
Aug 20, 2013 OTC Daily Alert Stock Watch - Easton Pharmaceuticals (OTC: EAPH)
Aug 14, 2013 Easton Pharmaceuticals Announces It Has Ordered Ingredients towards Producing Final Test and Trial Samples of Its Re-Formulated Viorra and Other Recently Added Portfolio Products
Jul 9, 2013 Andrew Wellington Headlines Ivy Family Office Network New York City Mid Year 2013 Forum
Jun 8, 2013 Easton Pharmaceuticals Announces Three New Additional Products and a Revision to Its Viorra Flagship Product Towards Resuming Its Latin American & South East Asia Initiatives
Jun 6, 2013 Easton Pharmaceuticals, Inc. Announces Its Entrance into the Medical Marijuana Sector
Jun 5, 2013 Easton Pharmaceuticals Announces Neil Mellor as Senior Consultant, Chief Operations Officer
Relating Aug 23 pr:,EAPH "has entered into discussions with 2 private independent companies in Canada for a proposed joint venture or partnership where it would share in any revenues generated in the medical Marijuana industry. Both of the companies currently possess growers licenses within various Provinces in Canada with one of them having affiliations within a clinical marijuana friendly state."
NEIL MELLOR(only 3 months here) -THE COO IS a Genius:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91360366
As Mentioned above other MJ companies trading 20-150 times EAPH's CAP.but EAPH has better assets/liabilities ratio,and great SS.(250M A/S,127M O/S).
EAPH trading LESS than 1m cap(.0075 PPS),assets/liabilities >1
that's is why we think EAPH could be a life changer.
EAPH: First Viorra Marketing Advertisement on the Web:
http://www.pearlwhitemediahosting.com/emerging/
Why is it new:
Just click on the web page at the bottom of my post.
Then you scroll right to the bottom of that page...
On the left side you will see.
Those 2 lines are indicating 2 things
The copyright: Emerging Women's Healthcare. Google it, you will find nothing. So it's brand new...
And the Designer of that web page: Montreal Web Design by Pearlwhitemedia.com
That last line is clickable to bring you to their site.
The copyright of Pearl White Media is dated 2013.
So, again the Viorra Marketing advertisement cannot be very old.
Moreover, the web page address is still: www.pearlwhitemediahosting.com/emerging/,
instead of Emerging Women's Healthcare or whatever...
I really think that Neil Mellor is just starting the marketing campaign about Viorra.
He probably gave the first contract to Pearl White Media Inc..
That web page may still need some SEO,SERP,SEM,SEA,SMO,SMM,SERM... optimizations before being approved by Neil.
Then, that web page will have a different address, probably: Emerging Women's Healthcare, or it may be integrated into the future website: http://www.ashleybiomedical.com/ , for the part 2 of the advertisement campaign, just before going Viral.
Date : 09/27/2013 @ 9:00AM
Source : Business Wire
Stock : Easton Pharmaceuticals, Inc. (PC) (EAPH)
Quote : 0.005 0.0 (0.00%) @ 5:32AM
§
Easton Pharmaceuticals Signs LOI to Acquire a Cosmetic Anti-Aging & Beauty Care Line of Products Including a Product to Compl...
Alert
Easton Pharmaceuticals, Inc. (PC) (USOTC:EAPH)
Intraday Stock Chart
Today : Friday 27 September 2013
Click Here for more Easton Pharmaceuticals, Inc. (PC) Charts.
Easton Pharmaceuticals, Inc. (OTC: EAPH) a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, today announces it has signed a letter of intent to acquire a line of Anti-Ageing and beauty care products.
The company has 60 days to perform its due diligence and review the line of products as well as any intellectual property including any patents or patent pendings that may come with the acquisition. The list of products includes an Anti-Ageing HEMP based Anti-Ageing Moisturizer, a product fortified with HEMP oil which is derived from a different form of Cannabis plant known to have high amounts of proteins and amino acids to compliment the companies medical Marijuana initiatives. As well as encompassing HEMP oil, the HEMP based Anti-Ageing moisturizer uses pure botanical natural ingredients derived from plants, including organic herbs. Other products include a specialized anti-ageing serum fortified with high amounts of Vitamin C, a skin discoloration / age spot treatment gel and an anti-cellulite varicose veins treatment system.
The Product line and the company the products are being acquired from will stay confidential until closing of a final definitive agreement, which the company believes has a high probability of closing. Both companies have 60 days in which to come to terms and close on the final agreement. Whether the transaction closes or not, it is anticipated that Easton will be providing assistance to these products by lending the use of its own technology to help improve the products efficacy and delivery through the skin. Should the deal close, this acquisition will bring Easton into the $426 Billion a year Cosmetics Industry which will coincide and complement its therapeutic line of products including its main product, “VIORRA”, a product to help treat FSAD (Female Sexual Arousal Disorder) utilizing ingredients which the FDA classifies as safe (GRAS).
In other developments, the Company has received its shipment of its main ingredient HA for final trial batch samples of Viorra and its other products, but is still waiting on additional ingredients which are expected shortly. Once complete, the trial samples will be shipped to Mexico and other parts of Latin America where the company anticipates completing and obtaining governmental regulatory approval which would allow the products to be sold in those vast markets. Although its new revised website has experienced delays for various reasons including final design labeling, all of these products as well as its current line of therapeutic products and recently acquired FSAD Drug will be listed and detailed very shortly.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered drugs, therapeutic healthcare products and beauty anti-aging cosmetic products. Its therapeutic healthcare products are focused on conditions that impact a large and expanding number of consumers including health and lifestyle issues related to female and male sexual dysfunction, treatment of certain pain, wound healing, scar and stretch marks, cellulite and varicose veins. The world market for these conditions is in excess of $10 billion while the world market for anti-ageing / beauty cosmetics is estimated at over $426 Billion.
The company's updated gel formulation is an innovative and thought to be unique transdermal delivery system. Easton Pharmaceuticals’ flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women’s sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
For More Information Visit
http://www.eastonpharma.com http://www.ashleybiomedical.com
Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company's financial reports and filings.
Contact:
Carla Pepe, Marketing Director
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Media and Investor Relations: info@lamindustries.com & info@ashleybiomedical.com
Easton Pharmaceuticals Inc.
Carla Pepe, Marketing Director
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
or
Media and Investor Relations:
info@lamindustries.com
info@ashleybiomedical.com
Mit dem Potential aus der aktuellen News kann es jetzt ganz schnell wieder über 0,01 $ gehen.
Easton Pharmaceuticals Announces Application to Obtain a Distributorship License Towards Its Canadian Medical Marijuana Initiatives
Optionen
| Boardmail an "skues1" |
Wertpapier: Easton Pharmaceuticals |
October 22, 2013, 8:06 a.m. ET Easton Pharmaceuticals Announces Formal Agreement & Advances Payment to BMV Medica S.A. Towards a Regulatory Filing in Mexico for "Viorra"; Company Anticipates Approval and Initial Sales by End of Second Quarter 2014.
http://online.wsj.com/article/...31022-906323.html?mod=googlenews_wsj
Optionen
| Boardmail an "skues1" |
Wertpapier: Easton Pharmaceuticals |
".......BMV has provided what it believes to be realistic projections towards possible sales figures that could be attained once an approval has been granted by regulatory authorities in Mexico. BMV believes an approval in Mexico would allow for instantaneous approvals and acceptance by governments in other parts of Latin America which opens up another huge potential market for VIORRA. According to BMV, Sales targets could reach between $10 to $14 million USD within 24 months of launch. These projections are based around other previously approved products, the size of the market, and the belief that a VIORRA type product would be eagerly accepted by women in these markets with a proper distribution partner. As conveyed by BMV, they have entered into discussions on Easton's behalf with several targeted distribution companies focused on sales and marketing in the women's health, sexual arousal disorder and the sexual wellness market.
Ms. Mendoza Vazquez of BMV, stated: "Once we finalize the discussions to secure a local high-quality manufacturing facility here in Mexico, the timelines towards regulatory approval can be shortened. As in other industries, Mexico has a highly skilled work force, with advantageous cost structures for pharmaceutical manufacturing. In addition, if properly marketed we believe Viorra could be the market leader in this segment, and very quickly attain the sales levels of similar products marketed for men, which we have seen to be in the tens of millions of dollars annually."
Optionen
| Boardmail an "skues1" |
Wertpapier: Easton Pharmaceuticals |
Optionen
| Boardmail an "skues1" |
Wertpapier: Easton Pharmaceuticals |